Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;36(3):543-53.
doi: 10.1007/s10545-012-9528-4. Epub 2012 Sep 14.

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment

Neal J Weinreb  1 , Jack Goldblatt, Jacobo Villalobos, Joel Charrow, J Alexander Cole, Marcelo Kerstenetzky, Stephan vom Dahl, Carla Hollak
Affiliations

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment

Neal J Weinreb et al. J Inherit Metab Dis. 2013 May.

Erratum in

  • J Inherit Metab Dis. 2014 Jan;37(1):147

Abstract

Objective: We studied the effect of long-term alglucerase/imiglucerase (Ceredase®/Cerezyme®, Genzyme, a Sanofi company, Cambridge, MA, USA) treatment on hematological, visceral, and bone manifestations of Gaucher disease type 1 (GD1).

Methods: The International Collaborative Gaucher Group (ICGG) Gaucher Registry identified GD1 patients treated with alglucerase/imiglucerase who had dose and clinical data at first infusion and after 10 years of follow-up. Data for hemoglobin, platelet count, organ volumes, bone pain, and bone crisis were analyzed. Tests of the null hypothesis (no change from first infusion to 10 years) were performed using t tests for within-patient absolute change in continuous measurements and McNemar/chi-square tests for change in distributions using categorical values. An alpha level of 0.05 designated statistical significance.

Results: As of October 2011, 557 nonsplenectomized and 200 splenectomized patients met the inclusion criteria. The majority of GD1 patients had at least one N370S allele. Compared with nonsplenectomized patients at first infusion, splenectomized patients had lower percentages of anemia (26.0 % vs. 42.8 %) and thrombocytopenia (14.2 % vs. 76.3 %), similar percentages of moderate or severe hepatomegaly (81.2 % vs. 80.0 %), and higher percentages of bone pain (88.9 % vs. 52.4 %) and bone crises (38.3 % vs. 16.0 %). After 10 years, both groups showed significant (p < 0.05) improvements in mean hemoglobin levels, platelet count, liver, and spleen (nonsplenectomized) volumes, and bone crises. Initial dosing in both groups ranged from <15 U/kg to ≤90 U/kg every 2 weeks. After 10 years, the majority was receiving 15 to ≤45 U/kg every 2 weeks.

Conclusion: Ten years of imiglucerase treatment results in sustainable improvements in all GD1 parameters.

PubMed Disclaimer

Conflict of interest statement

Neal Weinreb receives honoraria and expense reimbursement for serving on a Board of Advisors of the ICGG Gaucher Registry; and travel reimbursements and/or honoraria and/or research support from Genzyme, Shire Pharmaceuticals, Amicus Therapeutics, Protalix Corporation, and Actelion. He has been a study safety board advisor for Synageva Corporation. Jack Goldblatt has received reimbursements and/or honoraria from Genzyme, Shire Pharmaceuticals, Pfizer, Protalix and Actelion. Joel Charrow receives honoraria and expense reimbursement for serving on a Board of Advisors of the ICGG Gaucher Registry and the Fabry Registry and has received consulting fees from Shire Pharmaceuticals and Protalix. Carla Hollak has received honoraria and expense reimbursement for serving on a Board of Advisors of the European ICGG Gaucher Registry, and honoraria and expense reimbursement for lectures from Genzyme, Actelion and Shire Pharmaceuticals. Dr. Hollak donates all honoraria to Gaucher Stichting, a national foundation that supports research in the field of lysosomal storage disorders. Stephan vom Dahl has received honoraria and expense reimbursement for serving on a Board of Advisors of the European ICGG Gaucher Registry, fees for speaking from Genzyme, Shire, Protalix and Actelion and consulting for Actelion. Marcelo Kerstenetzky has received fees for consulting from Genzyme and Biomarin. Jacobo Villalobos has received fees for speaking from Genzyme. J. Alexander Cole is an employee of Genzyme.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005;7:105–110. doi: 10.1097/01.GIM.0000153660.88672.3C. - DOI - PubMed
    1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324:1464–1470. doi: 10.1056/NEJM199105233242104. - DOI - PubMed
    1. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31:337–349. doi: 10.1007/s10545-008-0832-y. - DOI - PubMed
    1. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835–2843. doi: 10.1001/archinte.160.18.2835. - DOI - PubMed
    1. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71:205–211. doi: 10.1111/j.1399-0004.2007.00769.x. - DOI - PubMed

Publication types